The CXCR4/SDF-1 chemokine receptor axis: A new target therapeutic for non-small cell lung cancer

61Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Chemokines are proinflammatory chemoattractant cytokines that regulate cell trafficking and adhesion. The CXCR4 chemokine receptor and its ligand, stromal cell derived factor (SDF-1), constitute a chemokine/receptor axis that has attracted great interest because of an increasing understanding of its role in cancer, including lung cancer. The CXCR4/SDF-1 complex activates several pathways that mediate chemotaxis, migration and secretion of angiopoietic factors. Neutralization of SDF-1 by anti-SDF-1 or anti-CXCR4 monoclonal antibody in preclinical in vivo studies results in a significant decrease of non-small cell lung cancer metastases. Since anti-SDF-1/CXCR4 strategies have already been developed for use in combating human immunodeficiency virus infections, it is likely that these approaches will be used in clinical trials in non-small cell lung cancer in the very near future. © 2008 by the International Association for the Study of Lung Cancer.

Cite

CITATION STYLE

APA

Otsuka, S., & Bebb, G. (2008). The CXCR4/SDF-1 chemokine receptor axis: A new target therapeutic for non-small cell lung cancer. Journal of Thoracic Oncology, 3(12), 1379–1383. https://doi.org/10.1097/JTO.0b013e31818dda9d

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free